Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Protox receives $340,000 to develop lung cancer drug
The money came from the Industrial Research Assistance Program (IRAP) at the National Research Council (NRC). This program is designed to assist small and medium-sized enterprises in Canada.
The money came from the Industrial Research Assistance Program (IRAP) at the National Research Council (NRC). This program is designed to assist small and medium-sized enterprises in Canada.
The compound NGX267 is a selective cholinergic muscarinic receptor agonist (M1 subtype) with properties suggesting the potential for both symptomatic and disease modification therapy in Alzheimer’s disease. The
Approval is sought for the use of Revlimid to treat myelodysplastic syndrome (MDS) patients with deletion 5q chromosomal abnormality. FDA review milestones will be communicated to Celgene in
As part of a plan to expand the market opportunities for its current pharmacogenetics service offering, Genaissance selected INC Research as its first contract research organization partner. Genaissance’s
Solgar, a manufacturer of nutritional supplements, had sales of approximately $105 million in 2004. Included in the company’s products are premium-branded multivitamins, minerals, botanicals and specialty formulas designed
The company intends to deploy the majority of its resources to advance the Gvax vaccine for prostate cancer, leukemia and pancreatic cancer. All of which are currently undergoing
The second letter of notice sent to Shire by Teva advises of an amendment to Teva’s existing application for generic versions of Adderall XR. The amendment is directed
The research was set up to address the activity of chemically modified short interfering RNA (siRNA) in a mouse model of hepatitis B virus replication. The data provides
Lorus believes this endorsement indicates that the product has the potential to provide efficacy and a significant benefit to patients with this devastating condition. The new status of
This designation provides Antigenics with, among other benefits, ten years of potential market exclusivity if the product is approved for marketing in the European Union (EU). The FDA